The Food and Drug Administration (FDA) recently authorized the marketing of three new tobacco products, marking the first set of electronic nicotine delivery system (ENDS) products to be authorized by FDA through the Premarket Tobacco Product Application (PMTA) pathway. The agency issued Marketing Granted Orders to R.J. Reynolds Vapor Company for its Vuse Solo closed ENDS device and accompanying tobacco-flavored e-liquid pods. The FDA has noted that this authorization allows these products to be legally sold in the U.S.—it does not mean these products are safe or “FDA approved.”
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
On Friday, May 28, President Biden released his full Fiscal Year (FY) 2022 budget request, which expands on the ‘skinny’ budget released in early April 2021. The full budget request includes an increase in funding for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and would fully fund the 21st Century Cures Act and the Beau Biden Cancer Moonshot Initiative. While the budget request is non-binding, it does signal the President’s priorities to Congress, stakeholders, and the general public.
The U.S. Food and Drug Administration (FDA) announced plans to advance two proposed tobacco product standards within the next year that would ban menthol cigarettes and flavored cigars (including menthol-flavored cigars) from the marketplace in the United States. The proposed standards align with the American Society of Clinical Oncology’s recommendation that FDA ban the addition of menthol to cigarettes and other combustible tobacco products as a characterizing flavor.